Dr. Patrick M. Higgins, MD
Ophthalmology (Ophthalmology Physician)
1255 Broad St, Ste 104
Bloomfield, NJ 07003
Who else practices at this address →
Essex County includes primary care (34% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 615
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NJ license 25MA06558600 -
Retina Specialist (Ophthalmology) Physician
NJ license 25MA06558600
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morristown Medical Center Morristown, NJ
- Good Samaritan Hospital of Suffern Suffern, NY
- Clara Maass Medical Center Belleville, NJ
Medical groups
- Eye Centers of America LLC (128 clinicians)
- Ny Retina Eye Care, PLLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 615
- Services billed
- 333,519
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 19,983 | 83 |
| Imaging of retina | 1,632 | 656 |
| Established patient complete exam of visual system | 1,420 | 599 |
| Injection, ranibizumab, 0.1 mg | 1,180 | 82 |
| Injection of drug into eye | 1,077 | 238 |
| Extended exam of the back part of the eye with optic nerve drawing | 567 | 378 |
| Injection, aflibercept, 1 mg | 565 | 86 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 375 | 18 |
| Extended exam of the back part of the eye with retinal drawing | 222 | 196 |
| Established patient problem focused exam of visual system | 218 | 124 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Bloomfield, NJ | 271 |
| Latanoprost Other prescribers in Bloomfield, NJ | 163 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 114 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Bloomfield, NJ | 110 |
| Ketorolac Tromethamine Other prescribers in Bloomfield, NJ | 109 |
| Prolensa (bromfenac sodium) | 49 |
| Brimonidine Tartrate Other prescribers in Bloomfield, NJ | 44 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in Bloomfield, NJ | 41 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Bloomfield, NJ | 34 |
| Lumigan (bimatoprost) Other prescribers in Bloomfield, NJ | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 23 payments worth $1,705 in total to this clinician.
| Ocular Therapeutix, Inc. | $573 |
|---|---|
| Glaukos Corporation | $397 |
| Sight Sciences, Inc. | $121 |
| Regeneron Healthcare Solutions, Inc. | $120 |
| Tarsus Pharmaceuticals, Inc. | $107 |
| Biotissue Holdings Inc. | $107 |
| Ani Pharmaceuticals, Inc. | $75.17 |
| Apellis Pharmaceuticals, Inc. | $60.29 |
| Food and Beverage | $1,705 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 11 companies. The companies reported $3,552,350 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Ma…
Novartis Pharmaceuticals Corporation - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - Faricimab for Under represented Patients with DME
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - MAD to assess the safety tolerability and PK PD in nAMD patients
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - A phase iii multicenter observation comparator study of the efficacy safety and pharmacokinetics
Genentech, Inc. - A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
Kyowa Kirin, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.